Last reviewed · How we verify
NAC-GEMABR
At a glance
| Generic name | NAC-GEMABR |
|---|---|
| Also known as | Gemcitabine, nab-paclitaxel |
| Sponsor | Wakayama Medical University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAC-GEMABR CI brief — competitive landscape report
- NAC-GEMABR updates RSS · CI watch RSS
- Wakayama Medical University portfolio CI